Cycloastragenol is a potent telomerase activator in neuronal cells: Implications for depression management

NeuroSignals

Volumn 22, Issue 1, 2014, Pages 52-63

  Ip, Fanny C F ^a   Ng, Yu Pong ^a   An, H J ^a   Dai, Ying ^a   Pang, Hai Hong ^a   Hu, Yue Qing ^a   Chin, Allison C ^b   Harley, Calvin B ^b,c   Wong, Yung Hou ^a   Ip, Nancy Y ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b GERON CORPORATION   (United States)

^c Telome Health Inc   (United States)

Author keywords

Astragalus membranaceus; cAMP response element binding; NGF; Saponin; Telomerase reverse transcriptase; Telomere

Indexed keywords

AGLYCONE; ANTIDEPRESSANT AGENT; ASTRAGALOSIDE IV; CYCLIC AMP; CYCLOASTRAGENOL; IMIPRAMINE; PROTEIN BCL 2; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NERVE GROWTH FACTOR; SAPOGENIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DEPRESSION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KERATINOCYTE; MALE; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; WOUND CLOSURE; ANIMAL; DRUG EFFECTS; METABOLISM; MOUSE; PC12 CELL LINE; SYNTHESIS;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSION; HUMANS; KERATINOCYTES; MICE; NERVE GROWTH FACTOR; NEURONS; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SAPOGENINS; TELOMERASE;

EID: 84906042136     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000365290     Document Type: Article

References (58)

1. Blackburn EH: Telomeres and telomerase: the means to the end (Nobel lecture). Angew Chem Int Ed Engl 2010; 49: 7405-7421.
2. O'Sullivan RJ, Karlseder J: Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010; 11: 171-181.
3. Pinto AR, Li H, Nicholls C, Liu JP: Telomere protein complexes and interactions with telomerase in telomere maintenance. Front Biosci 2011; 16: 187-207.
4. Prowse KR, Greider CW: Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995; 92: 4818-4822.
5. Greenberg RA, Allsopp RC, Chin L, Morin GB, DePinho RA: Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 1998; 16: 1723-1730.
6. Armstrong L, Lako M, Lincoln J, Cairns PM, Hole N: mTert expression correlates with telomerase activity during the differentiation of murine embryonic stem cells. Mech Dev 2000; 97: 109-116.
7. Kruk PA, Balajee AS, Rao KS, Boh VA: Telomere reduction and telomerase inactivation during neuronal cell differentiation. Biochem Biophys Res Commun 1996; 224: 487-492.
8. Caporaso GL, Lim DA, Alvarez-Buylla A, Chao MV: Telomerase activity in the subventricular zone of adult mice. Mol Cell Neurosci 2003; 23: 693-702.
9. Cheng A, Shin-ya K, Wan R, Tang SC, Miura T, et al: Telomere protection mechanisms change during neurogenesis and neuronal maturation: newly generated neurons are hypersensitive to telomere and DNA damage. J Neurosci 2007; 27: 3722-3733.
10. Roy NS, Chandler-Militello D, Lu G, Wang S, Goldman SA: Retrovirally mediated telomerase immortalization of neural progenitor cells. Nat Protoc 2007; 2: 2815-2825.
11. Ferrón SR, Marqués-Torrejón MA, Mira H, Flores I, Taylor K, et al: Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis. J Neurosci 2009; 29: 14394-14407.
12. Fu W, Killen M, Culmsee C, Dhar S, Pandita TK, et al: The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function. J Mol Neurosci 2000; 14: 3-15.
13. Lee J, Jo YS, Sung YH, Hwang IK, Kim H, et al: Telomerase deficiency affects normal brain functions in mice. Neurochem Res 2010; 35: 211-218.
14. Rolyan H, Scheffold A, Begus-Nahrmann Y, Heinrich A, Liss B, et al: Telomere shortening reduces Alzheimer's disease amyloid pathology in mice. Brain 2011; 134: 2044-2056.
15. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, et al: Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004; 101: 17312-17315.
16. Porton B, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, et al: Telomerase levels in schizophrenia: a preliminary study. Schizoph Res 2008; 106: 242-247.
17. Lukens JN, Van Deerlin V, Clark CM, Xie SX, Johnson FB: Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimers Dement 2009; 5: 463-469.
18. Wolkowitz OM, Epel ES, Reus VI, Mellon SH: Depression gets old fast: do stress and depression accelerate cell aging? Depress Anxiety 2010; 27: 327-338.
19. Fu W, Begley JG, Killen MW, Mattson MP: Anti-apoptotic role of telomerase in pheochomocytoma cells. J Biol Chem 1999; 274: 7264-7271.
20. Zhu H, Fu W, Mattson MP: The catalytic subunit of telomerase protects neurons against amyloid beta-peptideinduced apoptosis. J Neurochem 2000; 75: 117-124.
21. Lu C, Fu W, Mattson MP: Telomerase protects developing neurons against DNA damage-induced cell death. Brain Res Dev Brain Res 2001; 131: 167-171.
22. Kang HJ, Choi YS, Hong SB, Kim KW, Woo RS, et al: Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci 2004; 24: 1280-1287.
23. Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, et al: TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 2008; 27: 3754-3760.
24. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al: Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009; 460: 66-72.
25. Jurk D, Wang C, Miwa S, Maddick M, Korolchuk V, et al: Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell 2012; 11: 996-1004.
26. Li J, Qu Y, Chen D, Zhang L, Zhao F, et al: The neuroprotective role and mechanisms of TERT in neurons with oxygen-glucose deprivation. Neuroscience 2013; 252: 346-358.
27. Iannilli F, Zalfa F, Gartner A, Bagni C, Dotti CG: Cytoplasmic TERT Associates to RNA granules in fully mature neurons: role in the translational control of the cell cycle inhibitor p15INK4B. PLoS One 2013; 8:e66602.
28. Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, et al: Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol 2008; 181: 7400-7406.
29. Zhu J, Lee S, Ho MK, Hu Y, Pang H, et al: In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator. Drug Metab Pharmacokinet 2010; 25: 477-486.
30. Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, et al: Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types. Planta Med 2012; 78: 115-121.
31. Imomnazarov BA, Isaev MI: Triterpene glycosides of astragalus and their genins XXXVI. Cycloartanes of Astragalus uninodus. Chem Nat Comp 2004; 27: 381.
32. Fathiazad F, Khosropanah MK, Movafeghi A: Cycloartane-type glycosides from the roots of Astragalus caspicus Bieb. Nat Prod Res 2010; 24: 1069-1078.
33. Wang P, Jou S, Chen W, Lee S: An improved oxidative cleavage method for large scale preparation of some acid-labile aglycones form glycosides. J Chin Chem Soc 2002; 49: 103-106.
34. Ng YP, Wu Z, Wise H, Tsim KW, Wong YH, et al: Differential and synergistic effect of nerve growth factor and cAMP on the regulation of early response genes during neuronal differentiation. Neurosignals 2009; 17: 111-120.
35. Fu WY, Chen Y, Sahin M, Zhao XS, Shi L, et al: Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nat Neurosci 2007; 10: 67-76.
36. Ip FC, Glass DG, Gies DR, Cheung J, Lai KO, et al: Cloning and characterization of muscle-specific kinase in chicken. Mol Cell Neurosci 2000; 16: 661-773.
37. Porsolt R, Bertin A, Jalfre M: Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1997; 229: 327-336.
38. Kulkarni SK, Mehta AK: Purine nucleoside-mediated immobility in mice: reversal by antidepressants. Psychopharmacology 1985; 85: 460-463.
39. Ma XC, Dang YH, Jia M, Ma R, Wang F, et al: Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013; 8:e56053.
40. Nibuya M, Nestler EJ, Duman RS: Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
41. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS: Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49: 753-762.
42. Gass P, Riva MA: CREB, neurogenesis and depression. Bioessays 2007; 29: 957-961.
43. Benito E, Barco A: CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models. Trends Neurosci 2010; 33: 230-240.
44. Sheng M, Thompson MA, Greenberg ME: CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 1991; 252: 1427-1430.
45. Mayr B, Montminy M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001; 2: 599-609.
46. Szabo NJ: Dietary safety of cycloastragenol from Astragalus spp.: subchronic toxicity and genotoxicity studies. Food Chem Toxicol 2014; 64: 322-334.
47. de Jesus BB, Schneeberger K, Vera E, Tejera A, Harley CB, et al: The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 2011; 10: 604-621.
48. Harley CB, Liu W, Blasco M, Vera E, Andrews WH, et al: A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res 2011; 14: 45-56.
49. Boukamp P: Skin aging: a role for telomerase and telomere dynamics? Curr Mol Med 2005; 5: 171-177.
50. Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF: Impaired wound healing. Clin Dermatol 2007; 25: 19-25.
51. Sevimli-Gür C, Onbalar I, Atilla P, Genç R, Cakar N, et al: In vitro growth stimulatory and in vivo wound healing studies on cycloartane-type saponins of Astragalus genus. J Ethnopharmacol 2011; 34: 844-850.
52. Malberg JE, Schechter LE: Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11: 145-155.
53. Perera TD, Coplan JD, Lisanby SH, Lipira CM, Arif M, et al: Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007; 27: 4894-4901.
54. Eisch AJ, Petrik D: Depression and hippocampal neurogenesis: a road to remission Science 2012; 338: 72-75.
55. Castrén E, Rantamäki T: The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010; 70: 289-297.
56. Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Gattaz WF, et al: Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry 2013; 21: 493-496.
57. Del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, Torrisi MR, et al: Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ 2005; 12: 1429-1438.
58. Massard C, Zermati Y, Pauleau AL, Larochette N, Metivier D, et al: HTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 2006; 25: 4505-4514.